PubRank

C Di Somma

Author PubWeight™ 61.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 2000 2.19
2 Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest 2002 2.09
3 Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 2013 2.00
4 The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000 1.40
5 Growth hormone and the heart. Clin Endocrinol (Oxf) 2001 1.18
6 The heart: an end-organ of GH action. Eur J Endocrinol 2004 1.16
7 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001 1.01
8 Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. J Clin Endocrinol Metab 2000 0.96
9 Colon motility and colo-anal reflexes in chronic idiopathic constipation. Effects of a novel enterokinetic agent cisapride. Eur J Clin Pharmacol 1984 0.95
10 Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005 0.91
11 Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999 0.90
12 Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000 0.90
13 The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest 2012 0.89
14 Colorectal cancer: relationship of histologic grading to disease prognosis. Tumori 1983 0.88
15 Hypopituitarism induced by traumatic brain injury in the transition phase. J Endocrinol Invest 2005 0.87
16 Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. Clin Endocrinol (Oxf) 2003 0.87
17 Growth hormone status in morbidly obese subjects and correlation with body composition. J Endocrinol Invest 2006 0.87
18 Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary 2001 0.87
19 The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features. Eur J Neurol 2009 0.86
20 Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997 0.85
21 Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients. Horm Metab Res 2011 0.84
22 Estrogens and health in males. Mol Cell Endocrinol 2001 0.84
23 Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 1999 0.84
24 Impaired cardiac performance in elderly patients with growth hormone deficiency. J Clin Endocrinol Metab 1999 0.84
25 Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). Growth Horm IGF Res 2004 0.83
26 Sentinel lymph node mapping opens a new perspective in the surgical management of early-stage breast cancer: a combined approach with vital blue dye lymphatic mapping and radioguided surgery. Semin Surg Oncol 1998 0.83
27 Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001 0.83
28 Role of IGF-I on PTH effects on bone. J Endocrinol Invest 2010 0.82
29 Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 2003 0.82
30 Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001 0.82
31 Autoimmunity as a possible cause of growth hormone deficiency. J Endocrinol Invest 2008 0.81
32 Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Eur J Neurol 2011 0.81
33 The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group. Eur J Surg Oncol 2005 0.81
34 Associated hormonal decline in aging: is there a role for GH therapy in aging men? J Endocrinol Invest 2005 0.81
35 Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. Growth Horm IGF Res 2003 0.81
36 Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. Clin Endocrinol (Oxf) 2001 0.80
37 Pattern of lymphatic drainage to the sentinel lymph node in breast cancer patients. J Surg Oncol 2000 0.80
38 The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest 2011 0.80
39 Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest 2008 0.80
40 Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest 2006 0.79
41 Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. Eur J Endocrinol 2000 0.79
42 [Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon]. Minerva Med 1983 0.79
43 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999 0.79
44 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999 0.79
45 Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clin Endocrinol (Oxf) 2000 0.79
46 Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. Eur J Endocrinol 1995 0.79
47 Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 2011 0.79
48 Hypothalamic-pituitary-adrenal axis in neuropsychiatric disorders. Ann N Y Acad Sci 1994 0.78
49 Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab 1996 0.78
50 Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. Andrologia 2000 0.78
51 Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. J Clin Endocrinol Metab 1999 0.78
52 Cardiological aspects of growth hormone and insulin-like growth factor-I. J Pediatr Endocrinol Metab 1998 0.78
53 Growth hormone and cardiac function. Ann Endocrinol (Paris) 2000 0.78
54 Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest 1997 0.77
55 The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab 1999 0.77
56 Impairment of bone status in patients with central diabetes insipidus. J Clin Endocrinol Metab 1998 0.77
57 The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 2007 0.77
58 Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease. J Endocrinol Invest 2005 0.76
59 Localization of the sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue dye and intraoperative gamma probe. Tumori 2000 0.76
60 HLA-DRB1* and allergy to Parietaria: linkage and association analyses. Hum Immunol 1999 0.76
61 Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency. J Endocrinol Invest 2008 0.76
62 Evaluation of function and structure of arterial wall in girls and young women with Turner syndrome. J Endocrinol Invest 2015 0.76
63 Somatopause: dismetabolic and bone effects. J Endocrinol Invest 2005 0.76
64 Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J Endocrinol Invest 1999 0.75
65 Endocrine changes (beyond diabetes) after bariatric surgery in adult life. J Endocrinol Invest 2013 0.75
66 Importance of spinal deformity index in risk evaluation of VCF (vertebral compression fractures) in obese subjects: prospective study. Eur Spine J 2013 0.75
67 Beyond waist circumference in an adult male population of Southern Italy: Is there any role for subscapular skinfold thickness in the relationship between insulin-like growth factor-I system and metabolic parameters? J Endocrinol Invest 2012 0.75
68 Cortisol and the muscle-bone axis: response to comments by Molfino et al. Osteoporos Int 2015 0.75
69 Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Minerva Endocrinol 2013 0.75
70 Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest 1998 0.75
71 Sentinel lymph node mapping in early-stage breast cancer: technical issues and results with vital blue dye mapping and radioguided surgery. J Surg Oncol 2000 0.75
72 CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomed Pharmacother 1994 0.75
73 Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. Clin Endocrinol (Oxf) 1998 0.75
74 Adjuvant post-operative radiotherapy vs radiotherapy plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer. A phase III randomized clinical trial. P.A.R. Cooperative Study Group. Eur J Surg Oncol 1995 0.75
75 Evaluation of GH deficiency by GHRH+arginine test and IGF-I levels in a large population of young, middle-aged and elderly patients who had undergone neurosurgery for tumor masses in the hypothalamus-pituitary area. J Endocrinol Invest 2002 0.75
76 New medical approaches in pituitary adenomas. Horm Res 2000 0.75
77 The role of sentinel lymph node biopsy in patients with stage I/II cutaneous melanoma. The clinical experience at the National Cancer Research Institute of Genoa, Italy. Tumori 2002 0.75
78 [Computerized dynamic endothermography of the gastrointestinal mucosa as an indirect index of the state of vascularization of the abdominal organs. A preliminary note]. Minerva Chir 1989 0.75
79 Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors. Pituitary 1998 0.75
80 Usefulness of CV 205-502 in a case of allergy to ergot-derived drugs. Horm Res 1992 0.75
81 Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994 0.75
82 [The surgery of breast carcinoma. 10 years of activity]. Minerva Chir 1997 0.75
83 Height, weight, height velocity of primary school population sample in Campania region. J Endocrinol Invest 1998 0.75
84 Three-dimensional computer-assisted design of plastic reconstructive surgery procedures. Stud Health Technol Inform 1996 0.75
85 The role of growth hormone in glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008 0.75
86 Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol (Oxf) 2000 0.75
87 Allergy to ergot-derived dopamine agonists. Lancet 1992 0.75
88 Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. J Endocrinol Invest 2002 0.75
89 [Evaluation of the functional modifications of the lower esophageal sphincter after use of the Angelchik prosthesis]. Chir Ital 1983 0.75
90 Effects of pirenzepine and atropine on gastroduodenal motor patterns in duodenal ulcer patients. Scand J Gastroenterol 1986 0.75
91 Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies. Neuroendocrinology 1996 0.75
92 The 17β-hydroxysteroid dehydrogenase type 3 deficiency: a case report of an 18-year patient and review of the literature. Minerva Endocrinol 2013 0.75
93 [A retrospective study on the efficacy of the treatment of functional dyspepsia. An evaluation of 166 cases]. Minerva Med 1991 0.75
94 Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. J Endocrinol Invest 1998 0.75
95 [Arteriovenous anastomoses as a pathogenetic factor in primary varices of the lower limb]. Minerva Med 1989 0.75
96 [Gastroduodenal kinetic activity. Possible role of the duodenal bulb in controlling gastric emptying]. Minerva Dietol Gastroenterol 1989 0.75
97 Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. J Endocrinol Invest 1997 0.75
98 [Evaluation of the effects of ranitidine on gastroduodenal motility in ulcer patients]. Minerva Dietol Gastroenterol 1988 0.75
99 Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults. J Endocrinol Invest 2009 0.75
100 Post-operative analgesia with tramadol: a controlled study compared with an analgesic combination. Int J Clin Pharmacol Res 1993 0.75
101 [Merkel's tumor. Some comments and the authors' personal cases]. Minerva Chir 1992 0.75